Marshall Wace LLP Has $35.27 Million Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

Marshall Wace LLP trimmed its position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 24.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 899,718 shares of the biopharmaceutical company's stock after selling 295,762 shares during the quarter. Marshall Wace LLP owned approximately 1.18% of Xenon Pharmaceuticals worth $35,269,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the company. State Street Corp lifted its position in Xenon Pharmaceuticals by 13.2% during the 3rd quarter. State Street Corp now owns 279,513 shares of the biopharmaceutical company's stock worth $11,004,000 after buying an additional 32,701 shares in the last quarter. Barclays PLC raised its stake in shares of Xenon Pharmaceuticals by 1,275.5% in the third quarter. Barclays PLC now owns 14,993 shares of the biopharmaceutical company's stock worth $590,000 after acquiring an additional 13,903 shares during the last quarter. JPMorgan Chase & Co. lifted its position in shares of Xenon Pharmaceuticals by 1,263.2% during the third quarter. JPMorgan Chase & Co. now owns 976,783 shares of the biopharmaceutical company's stock worth $38,456,000 after purchasing an additional 905,129 shares in the last quarter. Harbor Capital Advisors Inc. grew its stake in shares of Xenon Pharmaceuticals by 3.7% during the fourth quarter. Harbor Capital Advisors Inc. now owns 49,818 shares of the biopharmaceutical company's stock valued at $1,953,000 after purchasing an additional 1,755 shares during the last quarter. Finally, Elmwood Wealth Management Inc. raised its position in Xenon Pharmaceuticals by 44.7% in the 4th quarter. Elmwood Wealth Management Inc. now owns 11,007 shares of the biopharmaceutical company's stock worth $431,000 after purchasing an additional 3,400 shares during the last quarter. Institutional investors and hedge funds own 95.45% of the company's stock.

Xenon Pharmaceuticals Trading Down 0.4 %

Shares of XENE stock traded down $0.16 on Thursday, hitting $37.43. The stock had a trading volume of 183,927 shares, compared to its average volume of 441,046. The firm has a market cap of $2.87 billion, a P/E ratio of -13.28 and a beta of 1.21. Xenon Pharmaceuticals Inc. has a twelve month low of $26.74 and a twelve month high of $46.00. The company has a fifty day moving average price of $34.85 and a two-hundred day moving average price of $38.72.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.84) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.89) by $0.05. On average, analysts expect that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current year.

Insiders Place Their Bets

In other Xenon Pharmaceuticals news, CEO Ian Mortimer sold 22,468 shares of Xenon Pharmaceuticals stock in a transaction on Friday, January 24th. The shares were sold at an average price of $40.20, for a total transaction of $903,213.60. Following the completion of the transaction, the chief executive officer now directly owns 31,302 shares of the company's stock, valued at $1,258,340.40. The trade was a 41.79 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 5.52% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have commented on XENE shares. The Goldman Sachs Group decreased their price objective on Xenon Pharmaceuticals from $60.00 to $52.00 and set a "buy" rating on the stock in a research report on Thursday, April 17th. StockNews.com upgraded Xenon Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Thursday. HC Wainwright reissued a "buy" rating and set a $53.00 price objective on shares of Xenon Pharmaceuticals in a report on Monday, February 24th. Deutsche Bank Aktiengesellschaft began coverage on shares of Xenon Pharmaceuticals in a research note on Tuesday, February 11th. They issued a "buy" rating and a $67.00 target price on the stock. Finally, William Blair reissued an "outperform" rating on shares of Xenon Pharmaceuticals in a research note on Friday, February 28th. One analyst has rated the stock with a hold rating and ten have given a buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $56.78.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.